322 related articles for article (PubMed ID: 28851300)
1. Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
Falkenius J; Johansson H; Tuominen R; Frostvik Stolt M; Hansson J; Egyhazi Brage S
BMC Cancer; 2017 Aug; 17(1):584. PubMed ID: 28851300
[TBL] [Abstract][Full Text] [Related]
2. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
[TBL] [Abstract][Full Text] [Related]
4. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
5. Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.
Picard M; Pham Dang N; D'Incan M; Mansard S; Dechelotte P; Pereira B; Mondie JM; Barthelemy I
Br J Dermatol; 2014 Jul; 171(1):108-14. PubMed ID: 24602025
[TBL] [Abstract][Full Text] [Related]
6. Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients.
Tas F; Erturk K
Neoplasma; 2019 Jul; 66(4):631-636. PubMed ID: 31058533
[TBL] [Abstract][Full Text] [Related]
7. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
Massi D; Romano E; Rulli E; Merelli B; Nassini R; De Logu F; Bieche I; Baroni G; Cattaneo L; Xue G; Mandalà M
Eur J Cancer; 2017 Jun; 78():70-81. PubMed ID: 28412591
[TBL] [Abstract][Full Text] [Related]
8. The role of BRAF mutations in primary melanoma growth rate and survival.
Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.
Johansson CC; Egyházi S; Masucci G; Harlin H; Mougiakakos D; Poschke I; Nilsson B; Garberg L; Tuominen R; Linden D; Stolt MF; Hansson J; Kiessling R
Cancer Immunol Immunother; 2009 Jul; 58(7):1085-94. PubMed ID: 19039588
[TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
11. FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor.
Leslie C; Bowyer SE; White A; Grieu-Iacopetta F; Trevenen M; Iacopetta B; Amanuel B; Millward M
Pathology; 2015 Oct; 47(6):557-63. PubMed ID: 26308130
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha.
Tas F; Erturk K
Cancer Chemother Pharmacol; 2019 Sep; 84(3):521-526. PubMed ID: 30997532
[TBL] [Abstract][Full Text] [Related]
13. Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.
Dabrosin N; Sloth Juul K; Bæhr Georgsen J; Andrup S; Schmidt H; Steiniche T; Heide Øllegaard T; Bønnelykke Behrndtz L
Melanoma Res; 2019 Feb; 29(1):30-37. PubMed ID: 30299387
[TBL] [Abstract][Full Text] [Related]
14. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
15. High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma.
Falkenius J; Lundeberg J; Johansson H; Tuominen R; Frostvik-Stolt M; Hansson J; Egyhazi Brage S
Melanoma Res; 2013 Dec; 23(6):452-60. PubMed ID: 24128789
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma.
Mann GJ; Pupo GM; Campain AE; Carter CD; Schramm SJ; Pianova S; Gerega SK; De Silva C; Lai K; Wilmott JS; Synnott M; Hersey P; Kefford RF; Thompson JF; Yang YH; Scolyer RA
J Invest Dermatol; 2013 Feb; 133(2):509-17. PubMed ID: 22931913
[TBL] [Abstract][Full Text] [Related]
17. CD8⁺ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma.
Fujii H; Arakawa A; Utsumi D; Sumiyoshi S; Yamamoto Y; Kitoh A; Ono M; Matsumura Y; Kato M; Konishi K; Shiga T; Sano S; Sakaguchi S; Miyagawa-Hayashino A; Takahashi K; Uezato H; Miyachi Y; Tanioka M
Int J Cancer; 2014 May; 134(10):2393-402. PubMed ID: 24243586
[TBL] [Abstract][Full Text] [Related]
18. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G
Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532
[TBL] [Abstract][Full Text] [Related]
19. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of BRAF mutations in localized cutaneous melanoma.
Nagore E; Requena C; Traves V; Guillen C; Hayward NK; Whiteman DC; Hacker E
J Am Acad Dermatol; 2014 May; 70(5):858-62.e1-2. PubMed ID: 24388723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]